News Column

Cannabis Technologies Appoints Dr. Tarek S. Mansour, Ph.D. to Scientific Advisory Board

June 10, 2014



VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 10, 2014) - Cannabis Technologies Inc. (the company) (CSE:CAN)(OTCQB:CANLF) announces today that Tarek Mansour, Ph.D., a veteran executive of the Life Science sector, has joined its Scientific Advisory Board. Dr. Mansour has over 26 years of experience in drug discovery and development with senior leadership and management positions within the biotechnology and pharmaceutical sector.

"We are delighted to welcome Dr. Mansour as a scientific advisor to the Company," said Craig Schneider, President & CEO. "Dr. Mansour is a distinguished R&D executive with the experience of drug development discovery to commercialization. His experience and expertise in both biotechnology and pharmaceutical will be instrumental in guiding our strategic initiatives."

Dr. Mansour's industrial career started in 1989 with BioChem Pharma in Quebec; after which he joined Wyeth-Ayerst in 1997 as Assistant Vice-President to direct the medicinal chemistry efforts at the site in Pearl River, NY. In 2009, his responsibilities were expanded to head the Chemical Sciences Department at four discovery sites in the USA, as well as CRO support in India. After the Wyeth acquisition by Pfizer in 2009, Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline. Subsequently, in 2010 he became the Executive Vice-President of R&D for Xenon Pharmaceuticals in British Columbia, Canada until early 2013. In mid 2013, Dr. Mansour became the Founder and Chief Executive Officer of Sabila Biosciences LLC, New York.

Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.

Dr. Mansour received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemistry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the University of Missouri-Columbia, U.S.A. (1982) and a diploma in Applied Management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the Immunomedicinal Chemistry Chair.

About Cannabis Technologies ("CTI")

CTI is a biopharmaceutical drug discovery and development company uniquely focused on the pharmacology and therapeutic potential of cannabinoids.

CTI is utilizing its proprietary "Cannabinoid Drug Design Platform" to identify new bioactive compounds within the marijuana plant that interact with certain genes responsible for specific diseases.

Our extensive research and intellectual properties will initially be focused on the development of several new cannabinoid based treatments for Ocular, Cancer & Angiogenesis, and Inflammation, Pain.

ON BEHALF OF THE BOARD

Craig Schneider, President and CEO

For further information, please visit the company's website at www.cannabis-tech.com.

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause Cannabis Technologies actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and Cannabis Technologies disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FOR FURTHER INFORMATION PLEASE CONTACT: Cannabis Technologies Inc.Craig Schneider President and Chief Executive Officer 604.669.7207 604.683.2506 (FAX) info@cannabis-tech.comwww.cannabis-tech.com Source: Cannabis Technologies Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Marketwire (Canada)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters